Literature DB >> 11337520

Radiolabeled amino acids: basic aspects and clinical applications in oncology.

P L Jager1, W Vaalburg, J Pruim, E G de Vries, K J Langen, D A Piers.   

Abstract

As the applications of metabolic imaging are expanding, radiolabeled amino acids may gain increased clinical interest. This review first describes the basic aspects of amino acid metabolism, then continues with basic aspects of radiolabeled amino acids, and finally describes clinical applications, with an emphasis on diagnostic value. A special focus is on (11)C-methionine, (11)C-tyrosine, and (123)I-iodomethyltyrosine, because these have been most used clinically, although their common affinity for the L-transport systems may limit generalization to other classes of amino acids. The theoretic and preclinical background of amino acid imaging is sound and supports clinical applications. The fact that amino acid imaging is less influenced by inflammation may be advantageous in comparison with (18)F-FDG PET imaging, although tumor specificity is not absolute. In brain tumor imaging, the use of radiolabeled amino acids is established, the diagnostic accuracy of amino acid imaging seems adequate, and the diagnostic value seems advantageous. The general feasibility of amino acid imaging in other tumor types has sufficiently been shown, but more research is required in larger patient series and in well-defined clinical settings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337520

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  131 in total

1.  Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer.

Authors:  Delphine Denoyer; Laura Kirby; Kelly Waldeck; Peter Roselt; Oliver C Neels; Thomas Bourdier; Rachael Shepherd; Andrew Katsifis; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-13       Impact factor: 9.236

2.  [Preoperative imaging as the basis for image-guided neurosurgery].

Authors:  D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

Review 3.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

4.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

5.  Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas.

Authors:  Dan Ribom; Marjoleine Schoenmaekers; Henry Engler; Anja Smits
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  [PET/CT in radiotherapy].

Authors:  M Weckesser; S Könemann; M Brinkmann; N Willich; O Schober
Journal:  Radiologe       Date:  2004-11       Impact factor: 0.635

7.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?

Authors:  Gérard Moulin-Romsée; Eduard D'Hondt; Tjibbe de Groot; Jan Goffin; Raf Sciot; Luc Mortelmans; Johan Menten; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

8.  In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.

Authors:  Teréz Márián; Gábor Szabó; Katalin Goda; Henrietta Nagy; Nóra Szincsák; István Juhász; László Galuska; László Balkay; Pál Mikecz; Lajos Trón; Zoltán Krasznai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-27       Impact factor: 9.236

9.  Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.

Authors:  Hansjörg Vees; Srinivasan Senthamizhchelvan; Raymond Miralbell; Damien C Weber; Osman Ratib; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-26       Impact factor: 9.236

10.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.

Authors:  I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.